China, U.S. consumer protection MOU
This article was originally published in The Tan Sheet
As FDA and other agencies continue tests to determine whether bulk food and drug ingredients from China are contaminated, the Federal Trade Commission announces a memorandum of understanding with its Chinese counterpart to promote consumer protection cooperation. The non-binding MOU, which covers all products including drugs and dietary supplements, comes after FTC and China's State Administration for Industry and Commerce began work on consumer protection issues. "This is sort of a formal strengthening of the relationship that we agreed," says Jackie Dizdul, of FTC's Office of Public Affairs. FDA has ordered the detention without physical examination of all dentifrice products including aerosols, liquids, toothpastes and tooth powders with or without fluoride containing diethylene glycol after a sampling assignment discovered DEG in several Chinese products (1"The Tan Sheet" June 4, 2007, In Brief)
You may also be interested in...
FDA warns consumers not to use toothpaste labeled as made in China and issues an import alert June 1 to prevent toothpaste containing toxic diethylene glycol from entering the country. One shipment of toothpaste containing 3% DEG has been identified and detained at the U.S. border by agency inspectors, and DEG-containing toothpaste also was found at a distribution center and a retail store, FDA states. No U.S. incidents of poisoning from toothpaste adulterated with DEG have been reported, according to the agency. Panama's health ministry also recently found DEG in Chinese-manufactured toothpastes, which in part contributed to FDA's increased scrutiny of toothpaste and other dental products made in China, FDA says (1"The Tan Sheet" May 28, 2007, In Brief)...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.